Abstract Number: 739 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in the Treatment of Refractory Systemic Lupus Erythematosus: Results from a National Register
Background/Purpose: Response to the anti-CD20 agent rituximab (RTX) in SLE is variable but it is still widely used for refractory SLE. Our aim was to…Abstract Number: 740 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment
Background/Purpose: Lack of adherence to treatment recommendations is a serious confounder to assessment of treatment efficacy for systemic lupus erythematosus (SLE). Estimates of nonadherence with…Abstract Number: 741 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients
Background/Purpose: Hydroxychloroquine (HCQ) is frequently used to treat autoimmune diseases. The HCQ package insert and online drug information resources report an increased risk of hemolytic…Abstract Number: 742 • 2016 ACR/ARHP Annual Meeting
A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea
Background/Purpose: SLE is an autoimmune disease associated with elevated levels of B Lymphocyte Stimulator (BLyS). This study assessed the efficacy and safety of belimumab (BLyS-specific…Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…Abstract Number: 744 • 2016 ACR/ARHP Annual Meeting
Factors Related to Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus
Background/Purpose: To identify factors associated with blood concentrations of hydroxychloroquine (HCQ) and its major metabolite, N-desethylhydroxychloroquine (DHCQ), in patients with systemic lupus erythematosus (SLE) receiving…Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…Abstract Number: 747 • 2016 ACR/ARHP Annual Meeting
The Long-Term Outcomes on Leflunomide Treatment in Patients with Lupus Nephritis: A Twelve-Year Follow-up Study
Background/Purpose: Leflunomide(LEF) is an effective immunosuppressant. In China, one phase III study has reported that compared with cyclophosphamide, LEF in combination with prednisone was effective in the induction…Abstract Number: 748 • 2016 ACR/ARHP Annual Meeting
A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus
Background/Purpose: Intravenous (IV) belimumab 10 mg/kg is approved in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) as add-on to standard SLE therapy (SoC). This…Abstract Number: 749 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Background/Purpose: The addition of an anti-TWEAK monoclonal antibody to SOC LN therapy did not improve 52-week RR rates in proliferative LN despite observed pharmacodynamic effects.…Abstract Number: 750 • 2016 ACR/ARHP Annual Meeting
Predictors of Corticosteroid Use in the Systemic Lupus International Collaborating Clinics Inception Cohort – a Multivariate Analysis
Factors Associated With Oral Glucocorticoid Use in Systemic Lupus Erythematosus : Results From a Large International Inception Cohort. Jayne Little1, Mark Lunt1, Ben Parker1, Ian…Abstract Number: 751 • 2016 ACR/ARHP Annual Meeting
Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Background/Purpose: We evaluated the relationships between disease activity measures and C4d split products on erythrocytes (EC4d) in SLE subjects from a subset of the Hopkins…Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…Abstract Number: 753 • 2016 ACR/ARHP Annual Meeting
Vitamin D Improves Systolic Blood Pressure in SLE
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Both a cohort study and a randomized clinical trial have proven that Vitamin D supplementation improves SLE…
ACR Meeting Abstracts